

QIBA fMRI Biomarker Committee (BC) Meeting

Wednesday, February 16, 2022, at 11 a.m. (CT)

Meeting Summary

In attendance

Feroze Mohamed, PhD (Co-chair)

Jay Pillai, MD (Co-chair)

David Soltysik, PhD (Co-chair)

Shruti Agarwal, PhD

Ichiro Ikuta, MD, MMSc

Anthony Liu, PhD

Nancy Obuchowski, PhD

Kiran Talekar, MD

James Voyvodic, PhD

Yuxiang Zhou, PhD, DABR

RSNA staff

Susan Stanfa

Review of Previous Meeting Summary

- The 02.02.2021 meeting summary was approved as presented

Topics Discussed:

- Team agreed that remaining Profile work is required before advancement to Public Comment (stage 1)

Next Steps / Action Items:

- Best practice details to be added to appendices
- Section 4 Assessment Procedures to be completed
- Text to be added to Appendix B: Biomarker Usage
- Claims need to be finalized
 - Dr. Voyvodic to confirm values for peak activation when the Profile nears completion
 - Relationship between Center of Mass and Peak activation (t value) and reproducibility of one vs. the other to be confirmed
 - Suggestion to add separate Peak activation Claim
- Dr. Soltysik to accept proposed changes to document discussed as a BC and determine which areas still need editing, then the draft Profile will be distributed to fMRI BC members for comment
- Discussion on checklists to be continued during March 2 meeting
- Deadline for completing a draft of the Profile for internal review to be confirmed; June 1, 2022 (following May American Society of Neuroradiology meeting) was suggested

Next meeting: Wednesday, March 2, 2022, at 11 a.m. CT (1st & 3rd weeks of each month)

RSNA Staff attempt to capture all committee members participating in Zoom meetings. However, if attendees join only by phone, or do not use a recognizable name, identification is not possible. Participants are welcome to contact RSNA staff at giba@rsna.org if their attendance is not reflected on meeting summaries.